Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Perfect NEWS !

<< Previous

Bullboard Posts

Next >>

Comment by Moemoney42on Jul 26, 2021 9:53am

74 Views

Post# 33603792

RE:Perfect NEWS !

This compound is a game changer in the treatment and management of covid-19.. far better than vaccines IMHO.. no matter what the variant is this treatment with R-107 will stop the virus in its tracks.. nice..!! ;-)

Mick00333 wrote: The study at Royal Brompton & Harefield NHS Foundation Trust was the largest of its kind worldwide.

In this study, 35 Patients with COVID-19 pneumonia who were on ventilation were given inhaled nitric oxide as part of routine care when they were failing to respond to best standard treatments.

This led to significant improvements in oxygen levels and improvements in ventilatory efficiency at 24 hours and for up to five days.